Literature DB >> 11905410

Diffuse malignant epithelial mesotheliomas of the peritoneum in women: a clinicopathologic study of 25 patients.

Scott A J Kerrigan1, Rael T Turnnir, Philip B Clement, Robert H Young, Andrew Churg.   

Abstract

BACKGROUND: The behavior of diffuse peritoneal mesotheliomas in women and the possible relation between tumor morphology and outcome are uncertain. Reported survival has ranged from < 1 month to > 14 years, and a previous study found that tumor morphology could not be used reliably for predicting outcome. The authors examined the behavior of diffuse epithelial peritoneal mesotheliomas in women and the possible relation between pathologic features and outcome.
METHODS: Twenty-five female patients with diffuse peritoneal epithelial malignant mesotheliomas were divided into two groups: those who survived for < 4 years (60%) and those who survived for > 4 years (40%). Both groups were compared in terms of age, presentation, treatment, survival, tumor architecture, mitotic rate, necrosis, nuclear grade, and immunohistochemical profile.
RESULTS: Patients in the two groups were similar in terms of age at diagnosis (median ages, 50.7 years and 49.9 years), presentation, initial tumor burden, and treatment. In both groups, the most common initial clinical presenting features were ascites and abdominal pain. The tumors typically took the form of multiple nodules measuring < 1.5 cm in greatest dimension. Slightly less than 50% of patients in both groups received some form of chemotherapy or radiation therapy after undergoing tumor-reductive surgery or biopsy. Overall survival ranged from 1 month to 15 years. The median survival was 12 months in the group of women who survived for < 4 years and 7 years in the group of women who survived for > 4 years. Overall, 10 of 25 patients survived for > or = 5 years. One patient was alive with disease 15 years after diagnosis. Although there was a suggestion that the tumors in patients with short survival more often had solid architecture and high-grade nuclei, these findings were not significant statistically. The frequency of necrosis and the mitotic activity were the same in both groups.
CONCLUSIONS: The spectrum of diffuse epithelial peritoneal mesotheliomas in women includes tumors that are highly aggressive and behave much like pleural mesotheliomas, although a sizeable number of tumors, unlike the pleural tumors, are relatively indolent. However, because there do not appear to be morphologic features that reliably identify favorable tumors versus unfavorable tumors, aggressive therapy for all women with diffuse peritoneal mesotheliomas may be warranted.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11905410     DOI: 10.1002/cncr.10209

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  Malignant mesothelioma of the peritoneum: case reports and immunohistochemical findings including Ki-67 expression.

Authors:  Hiroshi Hirano; Takashi Fujisawa; Koichi Maekawa; Eriko Ohkubo; Akira Okimura; Kozo Kuribayashi; Takashi Nakano; Keiji Nakasho; Takashi Nishigami
Journal:  Med Mol Morphol       Date:  2010-03-26       Impact factor: 2.309

Review 2.  Malignant peritoneal mesothelioma: a review.

Authors:  Joseph Kim; Shanel Bhagwandin; Daniel M Labow
Journal:  Ann Transl Med       Date:  2017-06

3.  Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases.

Authors:  David B Chapel; Jefree J Schulte; Gudrun Absenger; Richard Attanoos; Luka Brcic; Kelly J Butnor; Lucian Chirieac; Andrew Churg; Françoise Galateau-Sallé; Kenzo Hiroshima; Yin P Hung; Hedy Kindler; Thomas Krausz; Alberto Marchevsky; Mari Mino-Kenudson; Jeffrey Mueller; Kazuki Nabeshima; Kirin Turaga; Ann E Walts; Aliya N Husain
Journal:  Mod Pathol       Date:  2020-10-15       Impact factor: 7.842

4.  Molecular characterization of diffuse malignant peritoneal mesothelioma.

Authors:  Yin P Hung; Fei Dong; Matthew Torre; Christopher P Crum; Raphael Bueno; Lucian R Chirieac
Journal:  Mod Pathol       Date:  2020-06-05       Impact factor: 7.842

Review 5.  Localized intrapancreatic malignant mesothelioma: a rare entity that may be confused with other pancreatic neoplasms.

Authors:  Rosanny Espinal-Witter; Elliot L Servais; David S Klimstra; Michael D Lieberman; Rhonda K Yantiss
Journal:  Virchows Arch       Date:  2010-02-11       Impact factor: 4.064

6.  Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma.

Authors:  Sheelu Varghese; Zhaorong Chen; David L Bartlett; James F Pingpank; Steven K Libutti; Seth M Steinberg; John Wunderlich; H Richard Alexander
Journal:  Cancer       Date:  2010-09-13       Impact factor: 6.860

7.  Experience with peritoneal mesothelioma at the Milan National Cancer Institute.

Authors:  Marcello Deraco; Dario Baratti; Antonello Domenico Cabras; Nadia Zaffaroni; Federica Perrone; Raffaella Villa; Jenny Jocollè; Maria Rosaria Balestra; Shigeki Kusamura; Barbara Laterza; Silvana Pilotti
Journal:  World J Gastrointest Oncol       Date:  2010-02-15

8.  Malignant peritoneal mesothelioma.

Authors:  Stine Munkholm-Larsen; Christopher Q Cao; Tristan D Yan
Journal:  World J Gastrointest Surg       Date:  2009-11-30

9.  [Pathologic and anatomic evidence of peritoneal metastases].

Authors:  I Tischoff; A Tannapfel
Journal:  Chirurg       Date:  2007-12       Impact factor: 0.955

10.  Changing trends in US mesothelioma incidence.

Authors:  H Weill; J M Hughes; A M Churg
Journal:  Occup Environ Med       Date:  2004-05       Impact factor: 4.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.